PCSA (Processa Pharma) Forward P/E Multiple

Processa Pharmaceuticals (PCSA) is competing in the oncology sector by developing modified drugs. The company focuses on treating solid tumors by optimizing therapy biodistribution. The unique redesign of legacy drugs provides patent protection and premium pricing power. The company's forward P/E ratio history reflects the dynamics of market valuations, with the metric settling at 0.00.

PCSA - processapharmaceuticals.com Forward P/E Multiple over the range 07/04/2022 - 11/10/2026

Metric breakdowns and analytics for Processa Pharma (PCSA)

- current price and projected stock value:

Stock Quotes Processa Pharmaceuticals|PCSA - Fair Value Consensus

- business market valuation indicators:

Market Capitalization Processa Pharmaceuticals Inc.|PCSA - Real Price to Acquire Entire Company

- book capitalization information:

Book Value per Share Processa Pharmaceuticals|PCSA - Book Capitalization|Market Value to Book Value Ratio processapharmaceuticals.com|PCSA - Total Business Assets

- issuer credit burden and liquidity indicators:

Total Debt to Capital Processa Pharmaceuticals|PCSA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Processa Pharmaceuticals|PCSA - Company Cumulative Debt|Debt to Book Capitalization Ratio Processa Pharmaceuticals Inc.|PCSA - Company Long-Term Loans and Borrowings|Company Short-Term Debt Processa Pharmaceuticals|Quick Liquidity processapharmaceuticals.com

- earnings and market ratios statistics:

PCSA - Final Profit|Expected Profit Processa Pharmaceuticals|PCSA - Market Cap to Earnings|Forward P/E Multiple Processa Pharmaceuticals|PCSA - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Processa Pharmaceuticals Inc.|PCSA - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Processa Pharmaceuticals|PCSA - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months processapharmaceuticals.com|PCSA - Expected net earnings per share growth this year|Earnings growth forecast for next year Processa Pharmaceuticals

Analysis of all company metrics:PCSA Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals (PCSA) bases its strategy on expanding into the solid tumor therapy segment by optimizing drug biodistribution for oncology patients. An analysis of the business's forward P/E allows for the correlation of current market capitalization with expected annual earnings, determining the asset's degree of overvaluation and forming a consensus regarding the company's long-term investment attractiveness.

Direct competitors

Projected Price to Earnings OLMA (Olema)|PBYI (pumabiotechnology.com) - Future Price to Earnings Multiple|Forward P/E Multiple GLSI (Greenwich LifeSciences, Inc)|ZNTL - Projected Price to Earnings|MacroGenics, Inc. - Forward P/E Multiple|PSTV - Forward P/E Multiple|eagleus.com (EGRX) - Future Price to Earnings